Benicar and Hepatic lesion - a phase IV clinical study of FDA data

Summary:

Hepatic lesion is reported as a side effect among people who take Benicar (olmesartan medoxomil), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Lipitor, and have Abdominal pain upper.

The phase IV clinical study analyzes which people have Hepatic lesion when taking Benicar. It is created by eHealthMe based on reports of 34,073 people who have side effects when taking Benicar from the FDA, and is updated regularly.

What is Benicar?

Benicar has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 36,002 Benicar users. Check the latest studies of Benicar.

What is Hepatic lesion?

Hepatic lesion is found to be associated with 670 drugs and 620 conditions by eHealthMe. Check the latest studies of Hepatic lesion.

On Jul, 19, 2026

34,073 people reported to have side effects when taking Benicar.
Among them, 17 people (0.05%) have Hepatic lesion.

Among these 17 people:

How long have people been on Benicar when they have Hepatic lesion? *

What is the gender of people who have Hepatic lesion when taking Benicar? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Hepatic lesion when taking Benicar? *

What are other drugs people take besides Benicar? *

What are other side effects people have besides Hepatic lesion? *

Haemorrhoids (a swollen vein or group of veins in the region of the anus): 8 people, 47.06%
Gastric Ulcer (stomach ulcer): 8 people, 47.06%
Malabsorption (a state arising from abnormality in absorption of food nutrients across the gastrointestinal (gi) tract): 7 people, 41.18%
Celiac Disease - Sprue (a disease of the small intestine): 6 people, 35.29%
Stress And Anxiety: 6 people, 35.29%
Fatigue (feeling of tiredness): 6 people, 35.29%
Indigestion: 5 people, 29.41%
Haematemesis (vomiting of blood): 5 people, 29.41%
Diverticulum (out pouching of a hollow (or a fluid-filled) structure in the body): 5 people, 29.41%
Pancreatitis Chronic (chronic inflammation of pancreas): 4 people, 23.53%

What are the existing conditions these people have? *

Abdominal Pain Upper: 3 people, 17.65%
Type 2 Diabetes: 2 people, 11.76%
Pancreatic Neuroendocrine Tumor Metastatic: 2 people, 11.76%
Diarrhea: 2 people, 11.76%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 5.88%
Renal Cell Carcinoma (a kidney cancer): 1 person, 5.88%
Metastasis (spreadable cancer to other organ from origin): 1 person, 5.88%
Gastrointestinal Stromal Tumor: 1 person, 5.88%
Colon Cancer: 1 person, 5.88%
Breast Cancer Metastatic: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Benicar and have Hepatic lesion?

- Check whether Hepatic lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Benicar:

Benicar (36,002 reports)

Hepatic lesion treatments and more:

Hepatic lesion (5,726 reports)

Browse all side effects of Benicar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic lesion:

Hepatic lesion (670 drugs)

Browse all the conditions that are associated with Hepatic lesion:

Hepatic lesion (620 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Benicar) and Benicar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.